

Company Information and Disclosure Statement
Section One: Issuers' Quarterly Disclosure Obligations
for the For Period Ended June 30, 2017
LIFELINE BIOTECHNOLOGIES, INC.

OTCPK: LLBO

August 9, 2017

1) Name of the issuer and its predecessors (if any)

Exact Company Name:

Lifeline Biotechnologies, Inc. (hereinafter referred to as "The Company", "we", "us", or "our" or "the issuer")

There have been no other names of the Company during the most recent five years.

2) Address of the issuer's principal executive offices

Company Headquarters
1325 Airmotive Way, Suite 175, Reno, NV 89502
Phone: (775) 852-3222
Email: jholmes@lbt.com
Website: www.lbt.com

IR Contact: Jim Holmes at the above Company headquarters.

3) Security Information

Trading Symbol: LLBO
Exact title and class of securities outstanding: Common Stock
CUSIP: 53219E 80 8
Par Value: \$.00001
Total shares authorized: 4,950,000,000 as of: 6/30/17
Total shares outstanding: 3,138,880,967 as of 6/30/17

Preferred Shares Authorized: 12,500,000, Par Value: \$00001

Preferred Class A convertible 5,000,000 shares designated as of 6/30/17
Total Class A convertible shares outstanding: 4,855,708 as of 6/30/17

Preferred Class B convertible, 5,000,000 shares designated as of 6/30/17
Total Class B convertible outstanding: 1,286,535 as of 6/30/17

Transfer Agent

World Wide Stock Transfer
One University Plaza, Suite 505, Hackensack, NJ 07601
Phone: (201) 820-2008

Is the Transfer Agent registered under the Exchange Act?* Yes

List any restrictions on the transfer of security:

NONE

Describe any trading suspension orders issued by the SEC in the past 12 months.

NONE

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

NONE

4) Issuance History

List below any events, in chronological order, that resulted in changes in total shares outstanding by the issuer in the past two fiscal years and any interim period. The list shall include all offerings of equity securities, including debt convertible into equity securities, whether private or public, and all shares or any other securities or options to acquire such securities issued for services, describing (1) the securities, (2) the persons or entities to whom such securities were issued and (3) the services provided by such persons or entities. The list shall indicate:

- A. The nature of each offering (e.g., Securities Act Rule 504, intrastate, etc.);
Rule 144, settlement of debt
- B. Any jurisdictions where the offering was registered or qualified;
Nevada
- C. The number of shares offered;
92,200,000
- D. The number of shares sold;
92,200,000
- E. The price at which the shares were offered, and the amount actually paid to the issuer;
\$.0005, total \$44,968
- F. The trading status of the shares; and
Unrestricted
- G. Whether the certificates or other documents that evidence the shares contain a legend (1) stating that the shares have not been registered under the Securities Act and (2) setting forth or referring to the restrictions on transferability and sale of the shares under the Securities Act.
No legend or restriction

5) Financial Statements

Provide the financial statements described below for the most recent fiscal year end or quarter end to maintain qualification for the OTC Pink Current Information tier. For the initial disclosure statement (qualifying for Current Information for the first time) please provide reports for the two previous fiscal years and any interim periods.

The following Financial Statements have been posted to OTC Markets as of June 30, 2017 and December 31, 2016 and for the three months ended June 30, 2017 and 2016.

- A. Balance sheet
- B. Statement of income
- C. Statement of cash flows
- D. Financial notes

6) Describe the Issuer's Business, Products and Services

Describe the issuer's business so a potential investor can clearly understand the company. In answering this item, please include the following:

A. A description of the issuer's business operations:

The Company has developed, tested and patented a process that assists in the identification of dense breast tissue. The process is to be targeted as a screening protocol assisting in the early detection of breast tissue abnormalities and breast cancers. The Company licensed its affiliate, Cyrcadia, Inc. (name recently changed from First Warning Systems, Inc.). The license conveys the rights to Cyrcadia, Inc. to continue developing the patented technology and prepare and enter the market, worldwide. Lifeline received shares of Cyrcadia, Inc, a promissory note, which has been paid, and a revenue royalty on future sales. Prior to Cyrcadia's commencement of sales, Lifeline earns a minimum annual royalty.

Effective March 5, 2016, Lifeline Biotechnologies, Inc. ("Company") entered into an Intellectual Property Asset Option Agreement with Cyrcadia, Inc., a Nevada corporation ("Cyrcadia"). Under the Agreement, Cyrcadia was granted the exclusive right and option to acquire the worldwide right, title and interest in the Company's patents and other intellectual property associated with the Company's breast cancer detection technology. Cyrcadia is conducting clinical trials, planning to apply for regulatory clearance. Upon regulatory clearances Cyrcadia expects to pursue market launch, internationally and to provide the financial resources that are required to support these prospective value adds.

Under the Agreement, Cyrcadia had the right to exercise the option for a period of fifteen (15) months. In order to exercise the option and as the sole condition for its exercise, Cyrcadia was required to have raised not less than \$1,500,000 in additional working capital. Upon the exercise of the option, Cyrcadia is required to pay the Company \$330,000 in cash represented by two unsecured promissory notes and deliver to the Company 4,670,000 shares of Cyrcadia common stock and to reimburse the Company for its legal fees and costs in connection with the Agreement. Upon the exercise of the option, the current License Agreement between the Company and Cyrcadia dated September 12, 2012 will be terminated. Certain preliminary conditions prerequisite to the transfer have been defined however, Lifeline's management will decide in their sole judgment and discretion on the risks associated with Cyrcadia's prospects of achieving its business model, acceptable progress has and is being made, and that adequate financing is available, upon acceptable terms to Lifeline.

On March 2017, "CI" exercised the option. CI issued a \$330,000 promissory note to Lifeline payable in six \$55,000 monthly installments. Additionally, CI issued to Lifeline, 4,670,000 shares of its restricted common shares.

Lifeline transferred its patented technology to CI. Thereafter, Lifeline holds a total of 12,670,000 of CI's common shares, which represents approximately 47% of CI.

Shortly thereafter, CI licensed Cyrcadia Asia, Limited (CA) for manufacturing and marketing of CI's early breast cancer detection technology in Asian markets. CI received from CA, a royalty of \$1,050,000 payable over 50 months; a \$330,000 promissory note, payable over 6 months at \$55,000 per month; and a 2.5% equity interest in CA. The \$330,000 CA promissory note purchases 330,000 shares of CI's common stock at \$1.00 per share. Additionally, CA shareholders and affiliates purchased 500,000 common shares of CI at \$1.00 per share together with equal warrants expiring December 2018. CA committed to product development upgrades valued at approximately \$2.9 million. Once the upgrades are completed CA will license CI for distribution in CI's markets.

- B. Date and State (or Jurisdiction) of Incorporation: Incorporated November 6, 1981 – State of Nevada
- C. The issuer's primary and secondary SIC Codes: 8731
- D. The issuer's fiscal year end date: December 31
- E. Principal products or services, and their markets: Healthcare, breast cancer detection markets

7) Describe the Issuer's Facilities

The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer, give the location of the principal plants and other property of the issuer and describe the condition of the properties. If the issuer does not have complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership.

If the issuer leases any assets, properties or facilities, clearly describe them as above and the terms of its leases.

Leases office space at 1325 Airmotive Way, Suite 175, Reno, NV where the Company has resided for over 10 years. This office space is subleased to the Company's affiliate, Cyrcadia, Inc. The term of the lease is five year, ending on April 30, 2018.

8) **Officers, Directors, and Control Persons**

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant shareholders.

- A. Names of Officers, Directors, and Control Persons. In responding to this item, please provide the names of each of the issuer's executive officers, directors, general partners and control persons (control persons are beneficial owners of more than five percent (5%) of any class of the issuer's equity securities), as of the date of this information statement.

Jim Holmes, CEO, COB
c/o Lifeline Biotechnologies, Inc.
1325 Airmotive Way, Ste. 175
Reno, NV 89502

Jim Holmes became CEO of the Company in 2003 when the founder, William Reeves experienced health challenges. Prior to becoming CEO, Jim was the CFO since the mid 1990s. The primary focus has been to update the medical history documentation, interpretation and summarization of three rounds of patient testing. Lifeline's computer software system has been improved to the level of capabilities for patient data interpretation sensitivities and specificities potential capabilities in the 90% range. As a result three US software patents have been awarded. Mr. Holmes' previous work experience includes assistant controller of BioRad Labs, a New York Stock Exchange company; President of Harvest Brands, a public company traded OTC, which manufactured and distributed agricultural products. Mr. Holmes is a Certified Public Accountant, formerly with Price Waterhouse Coopers. He graduated from San Jose State University, with studies in business, accounting and economics; MBA studies at Golden Gate University and Stanford University's Advanced Management College.

Fred Schiemann, CPA, Board of Director and Chief Financial Officer and Controller

Mr. Schiemann has previously served as the Chief Financial Officer and director of various publicly listed Companies. Currently serves as CEO/CFO and Director of Biz2Biz.com and Viratech Corp. and CEO/CFO/Director of Interactive Health Network. Mr. Schiemann's educational background includes an undergraduate degree from the University of Illinois, Chicago Circle Campus as well as an MBA in taxation from Golden Gate University, Sacramento campus. During his years of practice, Mr. Schiemann has been involved with many public registrations and structuring of mergers and acquisitions. His current practice includes an emphasis on administration and consulting to small and micro-cap public companies.

- B. Legal/Disciplinary History. Please identify whether any of the foregoing persons have, in the last five years, been the subject of:
1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

None

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities:

None

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

None

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred suspended or otherwise limited such person's involvement in any type of business or securities activities.

None

- C. Beneficial Shareholders. Provide a list of the name, address and shareholdings or the percentage of shares owned by all persons beneficially owning more than ten percent (10%) of any class of the issuer's equity securities. If any of the beneficial shareholders are corporate shareholders, provide the name and address of the person(s) owning or controlling such corporate shareholders and the resident agents of the corporate shareholders.

Jim Holmes and Ann Holmes c/o Lifeline Biotechnologies, Inc. 1325 Airmotive Way, Ste 175 Reno, NV 89502	181,666,669 shares	6.0%
--	--------------------	------

Louis G. Keith, Trust. 1601 So. Halsted, Apt 508 Chicago, IL 60608	160,333,336 shares	5.3%
--	--------------------	------

9) Third Party Providers

Please provide the name, address, telephone number, and email address of each of the following outside providers that advise your company on matters relating to operations, business development and disclosure:

Legal Counsel

Robert Laskowski, Attorney at Law
520 SW Yamhill, Ste 600
Portland, OR 97204-1329
Phone: (503) 241-0780
Email: roblaw@hevanet.com

Accountant or Auditor

Fred Schiemann, Certified Public Accountant
429 W. Plumb Ln.
Reno, NV 89509
Phone: (775) 830-3663
Email: Fschiemann@yahoo.com

Investor Relations Consultant

NONE

Other Advisor - any other advisor(s) that assisted, advised, prepared or provided information with respect to this disclosure statement.

NONE

10) Issuer Certification

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles, but having the same responsibilities).

The certifications shall follow the format below:

I, Jim Holmes, certify that:

1. I have reviewed this Quarterly Report of Lifeline Biotechnologies, Inc.
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

August 9, 2017



Jim Holmes, CEO